Insmed Provides Update On IPLEX(TM) Expanded Access Program In Italy For The Treatment Of Amyotrophic Lateral Sclerosis

Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, provided an update on the IPLEX(TM) Expanded Access Program (EAP) in Italy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Since early 2007, the EAP has grown to include 15 physicians and approximately 70 subjects have been enrolled into the program. Additional subjects continue to be enrolled into the program.

More: continued here

Filed under: Clinical Trials on January 29th, 2008